Ira Winer, MD, PhD, discusses the tolerability of ALKS 4230 plus pembrolizumab in ovarian cancer.
Ira Winer, MD, PhD
Advertisement
Articles by Ira Winer, MD, PhD
Ira Winer, MD, PhD, assistant professor, Division of Gynecologic Oncology, Barbara Ann Karmanos Cancer Institute at Wayne State Cancer Institute, discusses immunotherapy in gynecologic malignancies.
Advertisement
Latest Updated Articles
Dr. Winer on the Tolerability of ALKS 4230 Plus Pembrolizumab in Ovarian CancerPublished: November 14th 2020 | Updated:
Dr. Winer Discusses Immunotherapy in Gynecologic MalignanciesPublished: April 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5